No CrossRef data available.
Article contents
Risk factors for the development of infections associated with carbapenemase-producing Enterobacteriaceae among previously colonized patients: A retrospective cohort study
Published online by Cambridge University Press: 20 November 2020
Abstract
Not all patients who acquire carbapenemase-producing Enterobacteriaceae (CPE) develop infections by these organisms; many remain only colonized. Of 54 CPE-colonized patients, 16 (30%) developed CPE infections. We identified indwelling urinary catheter exposure, exposure to intravenous colistin, and overseas transfer as variables associated with CPE infection development among colonized patients.
- Type
- Concise Communication
- Information
- Copyright
- © The Author(s), 2020. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
References
Division of Healthcare Quality Promotion. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). November 2015 update—CRE toolkit. Centers for Disease Control and Prevention website. http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf. Updated 2015. Accessed April 15, 2016.Google Scholar
Solter, E, Adler, A, Rubinovitch, B, et al. Israeli national policy for carbapenem-resistant enterobacteriaceae screening, carrier isolation and discontinuation of isolation. Infect Control Hosp Epidemiol 2018;39:85–89.CrossRefGoogle ScholarPubMed
Borer, A, Saidel-Odes, L, Eskira, S, et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae
. Am J Infect Control 2012;40:421–425.CrossRefGoogle ScholarPubMed
Tischendorf, J, de Avila, RA, Safdar, N. Risk of infection following colonization with carbapenem-resistant enterobactericeae: a systematic review. Am J Infect Control 2016;44:539–543.CrossRefGoogle ScholarPubMed
2019 NHSN patient safety component manual. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/validation/2019/pcsmanual_2019-508.pdf. Published 2019. Accessed October 26, 2020.Google Scholar
McConville, TH, Sullivan, SB, Gomez-Simmonds, A, Whittier, S, Uhlemann, A. Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study. PloS One 2017;12(10):e0186195.CrossRefGoogle ScholarPubMed
Tsuji, BT, Pogue, JM, Zavascki, AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39:10–39.CrossRefGoogle Scholar
Chew, KL, La, M, Lin, RT, Teo, JW. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of sensititre, MicroScan, vitek 2, and Etest with broth microdilution. J Clin Microbiol 2017;55:2609–2616.CrossRefGoogle ScholarPubMed
El-Sayed, A, Abd El-Gawad, M, Zhong, L, et al. Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019). Emerg Microb Infect 2020;9:868–885.CrossRefGoogle Scholar
Lo, E, Nicolle, L, Classen, D, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 2008;29 suppl 1:S41–S50.CrossRefGoogle Scholar